Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 15/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | KCNT1 | Q5JUK3 | 1/20 | 0.35 |
| ▸ | USP1 | O94782 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31661635 | 0.84 | S1PR1 (0.45) | S1PR1S1PR3 | |
| SCHEMBL31661573 | 0.81 | PTGS1 (0.41) | S1PR1USP1 | |
| SCHEMBL31661646 | 0.80 | S1PR1 (0.49) | S1PR1USP1 | |
| SCHEMBL31661691 | 0.80 | S1PR1 (0.38) | S1PR1HSP90AA1USP1 | |
| SCHEMBL31661641 | 0.79 | S1PR1 (0.46) | S1PR1S1PR3 | |
| SCHEMBL31661537 | 0.79 | NPC1 (0.41) | S1PR1S1PR3HSP90AA1USP1 | |
| SCHEMBL31661770 | 0.79 | S1PR1 (0.43) | S1PR1S1PR3HSP90AA1 | |
| SCHEMBL31661647 | 0.78 | NPC1 (0.44) | S1PR1PLATUSP1 | |
| SCHEMBL31661680 | 0.78 | NPC1 (0.38) | S1PR1USP1 | |
| SCHEMBL31661698 | 0.78 | USP1 (0.38) | S1PR1USP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151705-A1 | NOVEL INHIBITORS OF DNA DAMAGE REPAIR PATHWAY | VRISE THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| WO-2025151705-A1 | NOVEL INHIBITORS OF DNA DAMAGE REPAIR PATHWAY | VRISE THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | disclosed |